In a retrospective study focusing on compound mutations, 125 NSCLC patients with these alterations, excluding de novo exon 20 p.T790M compounds, received an EGFR TKI as first-line treatment [47]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.